Skip to main content
Premium Trial:

Request an Annual Quote

When the Ugly Duckling Grew Up, It Was a Beautiful Swan (Or Therapeutic)

Over at In the Pipeline, Derek Lowe blogs about the outcome of all those compounds that are discovered but can't be used as therapeutics. After looking at a particular compound that will never be used as a therapeutic, he writes, "But all this brings up another thing that we were talking about around here -- how much do drug companies owe academia for working out fundamental biochemistry and molecular biology? What if someone uses this very compound, for example, as a research tool and discovers something about its target that could be used to develop an actual drug?" (If you're thinking that you deserve credit for establishing the foundational research that was used to create some blockbuster drug, fuhgeddaboudit.)

 

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.